AMBTX-01

neridronate · Ambros Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AMBTX-01, covering 2026-03-31 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE) [Phase 3]